Novartis Ups The Ante In Immunotherapy With CoStim Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
The European pharma is increasing its stake in cancer immunotherapy with the acquisition of a start-up biotech that brings over late-stage assets against several targets.